Гистиоцитоз из клеток Лангерганса у взрослых: современные возможности терапии

ОБЗОРЫ , ,

В.Д. Латышев, Е.А. Лукина

ФГБУ «НМИЦ гематологии» Минздрава России, Новый Зыковский пр-д, д. 4, Москва, Российская Федерация, 125167

Для переписки: Виталий Дмитриевич Латышев, Новый Зыковский пр-д, д. 4, Москва, Российская Федерация, 125167; e-mail: LatyshevVD@gmail.com

Для цитирования: Латышев В.Д., Лукина Е.А. Гистиоцитоз из клеток Лангерганса у взрослых: современные возможности терапии. Клиническая онкогематология. 2021;14(4):444–54.

DOI: 10.21320/2500-2139-2021-14-4-444-454

РЕФЕРАТ

Гистиоцитоз из клеток Лангерганса (ГКЛ) — крайне редкое заболевание, обусловленное тканевой инфильтрацией патологическими клетками, имеющими фенотипическое сходство с нормальными клетками Лангерганса. Стандартная терапия ГКЛ у взрослых до настоящего времени не разработана ввиду отсутствия достаточной доказательной базы для тех или иных методов лечения. В клинической практике находит применение как цитостатическое лечение, так и новые подходы с использованием ингибиторов сигнальных путей, вовлеченных в патогенез ГКЛ. Настоящий литературный обзор посвящен существующим на текущий момент методам терапии ГКЛ у взрослых пациентов и возможностям их применения в клинической практике.

Ключевые слова: гистиоцитоз из клеток Лангерганса, терапия гистиоцитозов, мутация BRAFV600E, MAPK.

Получено: 20 июля 2021 г.

Принято в печать: 23 сентября 2021 г.

Читать статью в PDF

Статистика Plumx русский

ЛИТЕРАТУРА

  1. Лукина Е.А., Козловская А.С., Капланская И.Б., Мокеева Р.А. Гистиоцитоз X — Гистиоцитоз из клеток Лангерганса. Гематология и трансфузиология. 1990;35(9):10–5.
    [Lukina EA, Kozlovskaya AS, Kaplanskaya IB, Mokeeva RA. Histiocytosis X — Langerhans cell histiocytosis. Gematologiya i transfuziologiya. 1990;35(9):10–5. (In Russ)]
  2. Yu RC, Chu AC, Chu C, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. 1994;343(8900):767–8. doi: 10.1016/S0140-6736(94)91842-2.
  3. Willman CL, Busque L, Griffith BB, et al. Langerhans’-Cell Histiocytosis (Histiocytosis X) — A Clonal Proliferative Disease. N Engl J Med. 1994;331(3):154–60. doi: 10.1056/NEJM199407213310303.
  4. Badalian-Very G, Vergilio J-A, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–23. doi: 10.1182/blood-2010-04-279083.
  5. Braier J. Is Langerhans cell histiocytosis a neoplasia? Pediatr Blood Cancer. 2017;64(3):e26267. doi: 10.1002/pbc.26267.
  6. Egeler RM, Katewa S, Leenen PJM, et al. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci. Pediatr Blood Cancer. 2016;63(10):1704–12. doi: 10.1002/pbc.26104.
  7. Collin M, Bigley V, McClain KL, et al. Cell(s) of Origin of Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015;29(5):825–38. doi: 10.1016/j.hoc.2015.06.003.
  8. Allen CE, Beverley PCL, Collin M, et al. The coming of age of Langerhans cell histiocytosis. Nat Immunol. 2020;21(1):1–7. doi: 10.1038/s41590-019-0558-z.
  9. Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N Engl J Med. 2018;379(9):856–68. doi: 10.1056/NEJMra1607548.
  10. Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013;8(1):72. doi: 10.1186/1750-1172-8-72.
  11. Key SJ, O’Brien CJ, Silvester KC, et al. Eosinophilic granuloma: resolution of maxillofacial bony lesions following minimal intervention. Report of three cases and a review of the literature. J Cranio-Maxillofac Surg. 2004;32(3):170–5. doi: 10.1016/j.jcms.2004.01.004.
  12. Namai T, Yusa H, Yoshida H. Spontaneous remission of a solitary eosinophilic granuloma of the mandible after biopsy: A case report. J Oral Maxillofac Surg. 2001;59(12):1485–7. doi: 10.1053/joms.2001.28290.
  13. Esen A, Dolanmaz D, Kalayci A, et al. Treatment of localized Langerhans’ cell histiocytosis of the mandible with intralesional steroid injection: report of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2010;109(2):e53–8. doi: 10.1016/j.tripleo.2009.10.015.
  14. Watzke IM, Millesi W, Kermer C, et al. Multifocal eosinophilic granuloma of the jaw: Long-term follow-up of a novel intraosseous corticoid treatment for recalcitrant lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2000;90(3):317–22. doi: 10.1067/moe.2000.107535.
  15. Almuzayyen A, Elhassan W, Alabbadi M. Intralesional triamcinolone for treating mandibular Langerhans cell histiocytosis: A case report and literature review. Saudi J Med Med Sci. 2019;7(1):47. doi: 10.4103/sjmms.sjmms_84_17.
  16. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–14. doi: 10.1182/blood-2012-09-455774.
  17. Minkov M. Multisystem Langerhans Cell Histiocytosis in Children. Pediatr Drugs. 2011;13(2):75–86. doi: 10.2165/11538540-000000000-00000.
  18. Cantu MA, Lupo PJ, Bilgi M, et al. Optimal Therapy for Adults with Langerhans Cell Histiocytosis Bone Lesions. PLoS One. 2012;7(8):e43257. doi: 10.1371/journal.pone.0043257.
  19. Tazi A, Lorillon G, Haroche J, et al. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis. 2017;12(1):95. doi: 10.1186/s13023-017-0651-z.
  20. Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015;126(12):1415–23. doi: 10.1182/blood-2015-03-635151.
  21. Saven A, Figueroa ML, Piro LD, et al. 2-Chlorodeoxyadenosine to Treat Refractory Histiocytosis X. N Engl J Med. 1993;329(10):734–5. doi: 10.1056/NEJM199309023291013.
  22. Saven A, Burian C. Cladribine Activity in Adult Langerhans-Cell Histiocytosis. Blood. 1999;93(12):4125–30. doi: 10.1182/blood.V93.12.4125.
  23. Adam Z, Szturz P, Vanicek J, et al. Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases. Acta Oncol (Madr). 2013;52(5):994–1001. doi: 10.3109/0284186X.2012.716164.
  24. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood. 2015;126(1):26–35. doi: 10.1182/blood-2014-12-569301.
  25. Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Jt Bone Spine. 2019;86(3):301–7. doi: 10.1016/j.jbspin.2018.07.004.
  26. Steen AE, Steen KH, Bauer R, et al. Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. Br J Dermatol. 2001;145(1):137–40. doi: 10.1046/j.1365-2133.2001.04298.x.
  27. Cao X, Li J, Zhao A, et al. Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study. Blood. 2019;134(Suppl_1):294. doi: 10.1182/blood-2019-122220.
  28. Derenzini E, Stefoni V, Pellegrini C, et al. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. BMC Cancer. 2015;15(1):879. doi: 10.1186/s12885-015-1903-8.
  29. Tanimura S, Takeda K. ERK signalling as a regulator of cell motility. J Biochem. 2017;162(3):145–54. doi: 10.1093/jb/mvx048.
  30. Ducreux M, Chamseddine A, Laurent-Puig P, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol. 2019;11:175883591985649. doi: 10.1177/1758835919856494.
  31. Falini B, Martelli MP, Tiacci E. BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood. 2016;128(15):1918–27. doi: 10.1182/blood-2016-07-418434.
  32. Emile J-F, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–81. doi: 10.1182/blood-2016-01-690636.
  33. Крылов А.С., Долгушин М.Б., Рыжков А.Д. и др. Болезнь Эрдгейма–Честера. Обзор литературы и клинический случай. Онкогематология. 2020;15(2):61–75. doi: 10.17650/1818-8346-2020-15-2-61-75.
    [Krylov AS, Dolgushin MB, Ryzhkov AD, et al. Erdheim-Chester disease. Literature review and clinical case. Oncohematology. 2020;15(2):61–75. doi: 10.17650/1818-8346-2020-15-2-61-75. (In Russ)]
  34. Chakraborty R, Burke TM, Hampton OA, et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016;128(21):2533–7. doi: 10.1182/blood-2016-08-733790.
  35. Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. JAMA Oncol. 2018;4(3):384. doi: 10.1001/jamaoncol.2017.5029.
  36. Haroche J, Cohen-Aubart F, Emile J-F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–500. doi: 10.1182/blood-2012-07-446286.
  37. Ruan G, Goyal G, Abeykoon JP, et al. Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation. Blood. 2019;134(Suppl_1):5895. doi: 10.1182/blood-2019-124891.
  38. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med. 2012;367(18):1694–703. doi: 10.1056/NEJMoa1210093.
  39. Papapanagiotou M, Griewank KG, Hillen U, et al. Trametinib-Induced Remission of an MEK1-Mutated Langerhans Cell Histiocytosis. JCO Precis Oncol. 2017;1:1–5. doi: 10.1200/PO.16.00070.
  40. Lorillon G, Jouenne F, Baroudjian B, et al. Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion. Am J Respir Crit Care Med. 2018;198(5):675–8. doi: 10.1164/rccm.201802-0275LE.
  41. Sullivan RJ, Infante JR, Janku F, et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018;8(2):184–95. doi: 10.1158/2159-8290.CD-17-1119.
  42. Smalley I, Smalley KSM. ERK Inhibition: A New Front in the War against MAPK Pathway–Driven Cancers? Cancer Discov. 2018;8(2):140–2. doi: 10.1158/2159-8290.CD-17-1355.
  43. Sosman MC. Xanthomatosis. J Am Med Assoc. 1932;98(2):110. doi: 10.1001/jama.1932.02730280018005.
  44. Kriz J, Eich H, Bruns F, et al. Radiotherapy in Langerhans cell histiocytosis – a rare indication in a rare disease. Radiat Oncol. 2013;8(1):233. doi: 10.1186/1748-717X-8-233.
  45. Olschewski T, Seegenschmiedt MH. Radiotherapy of Langerhans’ Cell Histiocytosis. Strahlenther Onkol. 2006;182(11):629–34. doi: 10.1007/s00066-006-1630-9.
  46. Greenberger JS, Crocker AC, Vawter G, et al. Results of Treatment of 127 Patients with Systemic Histiocytosis (Letterer-Siwe Syndrome, Schuller-Christian Syndrome and Multifocal Eosinophilic Granuloma). Medicine (Baltimore). 1981;60(5):311–38. doi: 10.1097/00005792-198109000-00001.
  47. Furudate S, Fujimura T, Kambayashi Y, et al. Successful Treatment of Adult Onset Langerhans Cell Histiocytosis with Bi-weekly Administration of Pegylated Interferon-α. Acta Derm Venereol. 2014;94(5):611–2. doi: 10.2340/00015555-1807.
  48. El-Safadi S, Dreyer T, Oehmke F, et al. Management of adult primary vulvar Langerhans cell histiocytosis: review of the literature and a case history. Eur J Obstet Gynecol Reprod Biol. 2012;163(2):123–8. doi: 10.1016/j.ejogrb.2012.03.010.
  49. Ibrahim IF, Naina HVK. Treatment of recurrent Langerhans cell histiocytosis of the vulva with lenalidomide. J Clin Oncol. 2013;31(15_suppl):e16555. doi: 10.1200/jco.2013.31.15_suppl.e16555.
  50. Лукина Е.А., Кузнецов В.П., Беляев Д.Л. и др. Лечение гистиоцитоза Х (гистиоцитоз из клеток Лангерганса) препаратами α-интерферона. Терапевтический архив. 1993;11(65):67–70.
    [Lukina EA, Kuznetsov VP, Belyaev DL, et al. The treatment of histiocytosis X (Langerhans-cell histiocytosis) with alpha-interferon preparations. Terapevticheskii arkhiv. 1993;11(65):67–70. (In Russ)]
  51. Szturz P, Adam Z, Rehak Z, et al. Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncol (Madr). 2012;51(3):412–5. doi: 10.3109/0284186X.2011.631581.
  52. Zinn DJ, Grimes AB, Lin H, et al. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016;128(20):2462–5. doi: 10.1182/blood-2016-06-721993.
  53. Fleisch H. Bisphosphonates: Mechanisms of Action. Endocr Rev. 1998;19(1):80–100. doi: 10.1210/edrv.19.1.0325.
  54. Sivendran S, Harvey H, Lipton A, et al. Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series. Int J Hematol. 2011;93(6):782–6. doi: 10.1007/s12185-011-0839-2.
  55. Lebret T, Casas A, Cavo M, et al. The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies – a European survey. Eur J Cancer Care (Engl). 2017;26(4):e12490. doi: 10.1111/ecc.12490.
  56. Montella L, Merola C, Merola G, et al. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab. 2009;27(1):110–3. doi: 10.1007/s00774-008-0001-2.
  57. Elomaa I, Blomqvist C, Porkka L, et al. Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone. J Intern Med. 1989;225(1):59–61. doi: 10.1111/j.1365-2796.1989.tb00038.x.
  58. Arzoo K, Sadeghi S, Pullarkat V. Pamidronate for Bone Pain from Osteolytic Lesions in Langerhans’-Cell Histiocytosis. N Engl J Med. 2001;345(3):225. doi: 10.1056/NEJM200107193450318.
  59. Weitzman R, Sauter N, Eriksen EF, et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Crit Rev Oncol Hematol. 2007;62(2):148–52. doi: 10.1016/j.critrevonc.2006.12.005.
  60. Makras P, Tsoli M, Anastasilakis AD, et al. Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. Metabolism. 2017;69:107–11. doi: 10.1016/j.metabol.2017.01.004.
  61. Pan Y, Xi R, Wang C, et al. Autologous hematopoietic stem cell transplantation for efficient treatment of multisystem, high-risk, BRAF V600E-negative Langerhans cell histiocytosis. J Int Med Res. 2019;47(9):4522–9. doi: 10.1177/0300060519864807.
  62. Braier J, Rosso D, Pollono D, et al. Symptomatic Bone Langerhans Cell Histiocytosis Treated at Diagnosis or After Reactivation With Indomethacin Alone. J Pediatr Hematol Oncol. 2014;36(5):e280–е284. doi: 10.1097/MPH.0000000000000165001.
  63. gov [Internet]. LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis. Identifier NCT02205762. Available from: https://clinicaltrials.gov/ct2/show/NCT02205762 (accessed 21.07.2021).
  64. Kurtulmus N, Mert M, Tanakol R, et al. The pituitary gland in patients with Langerhans cell histiocytosis: a clinical and radiological evaluation. Endocrine. 2015;48(3):949–56. doi: 10.1007/s12020-014-0408-6.
  65. Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo-Pituitary Abnormalities in Adult Patients with Langerhans Cell Histiocytosis: Clinical, Endocrinological, and Radiological Features and Response to Treatment. J Clin Endocrinol Metab. 2000;85(4):1370–6. doi: 10.1210/jcem.85.4.6501.
  66. Abla O, Janka G, eds. Histiocytic Disorders. Cham: Springer International Publishing; 2018. doi: 10.1007/978-3-319-59632-7.
  67. Hutter C, Minkov M. Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies. ImmunoTarg Ther. 2016;5:81–91. doi: 10.2147/itt.s91058.